0089sek
-2,6 %
Date:2024-05-02Time:17:29:00Latest report:Q4-2023List:First NorthTicker:CYXO
Market Cap:19 msekEnterprise Value:3 msekNet Sales:- msekEarnings:-23,0 msekEmployees:0ISIN:SE0007815428

Ratios

10-year key figure history for Cyxone turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Cyxone with index and moving average MA50 and MA200.

Stockprice:0,089
MA50:0,09
MA200:0,20
Price/MA200:-55,2 %
RSI (14):49,4
Price/MA50:-0,4 %

Description

Cyxone AB is a clinical biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The product candidates of the company include T20K and Rabeximod.

Biotechnology